Clinical trials for MET-targeted therapies in NSCLC use varying definitions for MET amplification, including different Gene Copy Number (GCN) or MET-CEP7 ratio cutoffs. This inconsistency makes it challenging to compare drug efficacy and apply trial data directly to clinical practice.

Standard Next-Generation Sequencing (NGS) reports often just state "MET amplification" without a specific copy number. To make informed treatment decisions with MET inhibitors, clinicians must proactively contact the testing company's molecular pathology department to obtain this crucial, unlisted data point.

Beyond clinical validation, the adoption of novel biomarkers like microRNA is hindered by practical lab issues. Disagreements over sample type (serum vs. plasma), establishing universal cutoffs, and achieving high concordance between different testing centers are critical, non-clinical hurdles that must be overcome for widespread clinical use.

To ensure patients get the same result from any test provider, the field must standardize not just the underlying sequencing technology, but also the software pipelines for data analysis and the clinical frameworks for interpreting results. Each layer presents a unique harmonization challenge.

Clinicians must be cautious when interpreting genomic reports. A 'negative' result doesn't confirm the absence of a mutation; it only means the specific test, with its inherent limitations like an inability to detect copy number alterations, did not identify it. This distinction is critical for accurate diagnosis.

Clinicians must recognize that liquid and solid biopsies show significant discordance. ESR1 mutations are more frequently detected in liquid assays, while PIK3CA mutations are more often found in solid tissue. This variability by gene directly impacts the optimal testing strategy for patients.

Advanced imaging techniques can provide clues about a glioma's molecular subtype before surgery. Specifically, a 'T2-FLAIR mismatch' finding on an MRI is highly indicative of an IDH-mutant astrocytoma, allowing clinicians to anticipate the tumor's molecular profile and plan treatment strategies earlier.

Inconsistent methods for assessing biomarkers like PD-L1 (CPS vs. TAP scoring), p53 (IHC vs. sequencing), and HRR (different panels) across major clinical trials make it difficult to compare results and identify a reliable predictive marker for endometrial cancer.

Under current WHO guidelines, a histologically low-grade glioma can be reclassified as a high-grade (Grade 4) tumor based solely on molecular findings, such as a CDK2A/B deletion. This paradigm shift means molecular data is paramount, fundamentally changing patient prognosis and treatment strategy irrespective of microscopic appearance.